Isabella Rossi 11/27/23 Isabella Rossi 11/27/23

Elon Musk and Russell Brand in Moderna's Crosshairs: The Crusade Against Vaccine Dissent

David Stone 10/4/23 David Stone 10/4/23

How High Could the Stock Price of Gritstone Bio Go?

David Stone 8/19/23 David Stone 8/19/23

New Highly Mutated Covid-19 Variant BA.2.86 Detected in Multiple Countries

Isha Tanaka 5/2/23 Isha Tanaka 5/2/23

Trojan Horse Drug Delivery: The Future of Medicine and Matinas BioPharma's LNC Technology

David Stone 4/24/23 David Stone 4/24/23

Is BioNTech About to Take a Major Stake in Matinas BioPharma?

Isha Tanaka 4/16/23 Isha Tanaka 4/16/23

Moderna's Cancer Vaccine Shows Promising Results in Melanoma Prevention

Mark Armstrong 4/14/23 Mark Armstrong 4/14/23

How long do mRNA in-vivo studies take? A case study with Matinas and BioNTech

David Stone 4/3/23 David Stone 4/3/23

Future Uncertain as Matinas-BioNTech Agreement Nears End

Mark Armstrong 3/25/23 Mark Armstrong 3/25/23

Matinas BioPharma Website Goes Offline, Fueling M&A Speculation

Derek Slater 3/22/23 Derek Slater 3/22/23

Moderna's $130 COVID-19 Vaccine Price Tag Raises Concerns as Commercial Distribution Approaches

David Stone 3/19/23 David Stone 3/19/23

Revolutionizing mRNA Therapeutics: The Promise of a Novel Oral Drug Delivery System

Johnny Satireo 1/10/23 Johnny Satireo 1/10/23

Russia Appoints Jerome Jabbourk as Head of mRNA Research

Mark Armstrong 12/28/22 Mark Armstrong 12/28/22

New Chinese Covid Variants Could Drastically Affect the Stock Market in 2023

David Stone 10/31/22 David Stone 10/31/22

The expected value from a BioNTech and Matinas deal is off-the-charts bananas

David Stone 10/28/22 David Stone 10/28/22

3 reasons to sell BioNTech and buy Moderna

David Stone 7/25/22 David Stone 7/25/22

US Government plans to fund next generation Covid-19 vaccines

David Stone 6/12/22 David Stone 6/12/22

Matinas appears to be on the verge of signing a deal with BioNTech

David Stone 5/18/22 David Stone 5/18/22

Instead of a licensing agreement, BioNTech should just buy out Matinas

David Stone 4/21/22 David Stone 4/21/22

BioNTech’s Deal with Matinas Could Put Moderna Out of Business